US 12,466,878 B2
Peptides and combination of peptides for use in immunotherapy against cancers
Toni Weinschenk, Tuebingen (DE); Oliver Schoor, Tuebingen (DE); and Andrea Mahr, Tuebingen (DE)
Assigned to IMMATICS BIOTECHNOLOGIES GMBH, Tübingen (DE)
Filed by Immatics Biotechnologies GmbH, Tuebingen (DE)
Filed on Aug. 17, 2022, as Appl. No. 17/820,432.
Application 17/820,432 is a continuation of application No. 16/675,537, filed on Nov. 6, 2019, abandoned.
Application 16/675,537 is a continuation of application No. 15/458,893, filed on Mar. 14, 2017, granted, now 10,512,679, issued on Dec. 24, 2019.
Claims priority of provisional application 62/309,107, filed on Mar. 16, 2016.
Claims priority of application No. 1604490 (GB), filed on Mar. 16, 2016.
Prior Publication US 2023/0201321 A1, Jun. 29, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); A61K 39/00 (2006.01); A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); C07K 14/47 (2006.01); C07K 14/64 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); C12N 15/115 (2010.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01); G16B 25/00 (2019.01); G16B 25/10 (2019.01)
CPC C07K 16/18 (2013.01) [A61K 39/0011 (2013.01); A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); C07K 14/4743 (2013.01); C07K 14/64 (2013.01); C07K 14/70503 (2013.01); C07K 14/7051 (2013.01); C07K 16/00 (2013.01); C07K 16/2809 (2013.01); C12N 5/0638 (2013.01); C12N 15/115 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57484 (2013.01); G01N 33/6872 (2013.01); G16B 25/00 (2019.02); G16B 25/10 (2019.02); A61K 2039/572 (2013.01); A61K 2039/80 (2018.08); C07K 2319/40 (2013.01); C12N 2310/16 (2013.01); C12Q 2600/136 (2013.01); G01N 2333/70539 (2013.01)] 20 Claims
 
1. A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient a composition comprising a population of activated T cells that selectively recognize the cancer cells that present a peptide consisting of the amino acid sequence of KIQEILTQV (SEQ ID NO: 1),
wherein said cancer is selected from the group consisting of oral carcinoma, H. pylori-induced MALT lymphoma, Ewing's sarcoma, head and neck squamous cell carcinoma, epithelial cancer of the larynx, carcinoma of the urinary bladder, atypical meningioma, papillary thyroid carcinoma, salivary duct carcinoma, cervical cancer, and extranodal T/NK-cell lymphoma.